Logo image
Se connecter
Retour
Impact of Tafamidis on survival in elderly patients: Insights from the Healthcare European Amyloidosis Registry
Article de revue   Open Access   Avec comité de lecture

Impact of Tafamidis on survival in elderly patients: Insights from the Healthcare European Amyloidosis Registry

Antoine Jobbé-Duval, Mounira Kharoubi, Erwan Donal, Fabrice Bauer, Amaury Broussier, Arnaud Bisson, Océane Bouchot, Phillipe Charron, Jérôme Costa, Pierre-Yves Courand, …
International Journal of Cardiology, Vol.437
10/2025
DOI: https://doi.org/10.1016/j.ijcard.2025.133522
PMID: 40532791

Résumé

Tafamidis Survival Elderly Cardiac transthyretin amyloidosis ATTR-CM Aged Aged, 80 and over Registries Survival Rate Treatment Outcome Case-Control Studies Female Humans Male Amyloid Neuropathies, Familial Benzoxazoles Cardiomyopathies Europe Follow-Up Studies
Cardiac transthyretin amyloidosis (ATTR-CM) is a life-threatening cardiomyopathy. Tafamidis has been demonstrated to be an effective treatment. Our aim was to analyze clinical characteristics and survival of patients with ATTR-CM aged ≥80 years diagnosed after November 2018, treated with tafamidis 80/61 mg, and compare them with a non-treated group diagnosed before that date.

Fichiers et liens (2)

url
Find in HALAfficher
url
https://doi.org/10.1016/j.ijcard.2025.133522Afficher
Published (Version of record) Ouvrir

Indicateurs

1 Consultations de la notice

Détails

Logo image